2015
Biosimilar biologics: never identical but close enough
Abi‐Raad R, Smith BR. Biosimilar biologics: never identical but close enough. Transfusion 2015, 55: 229-231. PMID: 25683185, DOI: 10.1111/trf.12961.Peer-Reviewed Original Research
1996
The extracellular domain of CD45 controls association with the CD4-T cell receptor complex and the response to antigen-specific stimulation.
Leitenberg D, Novak TJ, Farber D, Smith BR, Bottomly K. The extracellular domain of CD45 controls association with the CD4-T cell receptor complex and the response to antigen-specific stimulation. Journal Of Experimental Medicine 1996, 183: 249-259. PMID: 8551228, PMCID: PMC2192406, DOI: 10.1084/jem.183.1.249.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SequenceAntigen PresentationBase SequenceCD4 AntigensCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell LineFlow CytometryImmunologic CappingLeukocyte Common AntigensLymphocyte ActivationMolecular Sequence DataPhenotypePhosphatidylinositol Diacylglycerol-LyasePhosphoric Diester HydrolasesProtein BindingReceptors, Antigen, T-CellRecombinant ProteinsStructure-Activity RelationshipTransfectionConceptsT cell receptorMolecular weight isoformsCD45 isoformsHigh molecular weight isoformsWeight isoformsAntigen-presenting cellsAntigen-specific stimulationT lymphocyte activationPanel of transfectantsLow molecular weight isoformsHigh molecular weight CD45 isoformsT helper 2 clonesCell receptor complexSpecific antigenT cell transfectants
1988
Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome.
Antin J, Smith B, Holmes W, Rosenthal D. Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome. Blood 1988, 72: 705-13. PMID: 3042046, DOI: 10.1182/blood.v72.2.705.bloodjournal722705.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAnemia, AplasticBlood Cell CountBone MarrowCell DivisionColony-Stimulating FactorsDose-Response Relationship, DrugDrug EvaluationFemaleGranulocyte-Macrophage Colony-Stimulating FactorGrowth SubstancesHumansMaleMiddle AgedMyelodysplastic SyndromesRecombinant ProteinsReticulocytesConceptsPhase I/II studyRecombinant human granulocyte-macrophage colony-stimulating factorAplastic anemiaGranulocyte-macrophage colony-stimulating factorMyelodysplastic syndromeColony-stimulating factorHuman granulocyte-macrophage colony-stimulating factorII studyReticulocyte countErythrocyte transfusion requirementsLow-grade feverMyalgia/arthralgiaMicrograms/m2Four-hour intravenous infusionNumber of eosinophilsGM-CSF therapyImmature myeloid cellsLow back discomfortTransfusion requirementsBlood countIntravenous infusionPlatelet countGranulocyte countMonocyte countPatientsPhase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in bone marrow failure.
Antin JH, Smith BR, Holmes W, David RN, Rosenthal S. Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in bone marrow failure. Behring Institute Mitteilungen 1988, 149-53. PMID: 3071331.Peer-Reviewed Original ResearchConceptsPhase I/II studyMicrograms/m2Bone marrow failureII studyMarrow failureGM-CSFSevere bone marrow failureErythrocyte transfusion requirementsMyalgia/arthralgiaLow-grade feverRecombinant human granulocyte-macrophage colony-stimulating factorGranulocyte-macrophage colony-stimulating factorSevere marrow failureLow back discomfortColony-stimulating factorHuman granulocyte-macrophage colony-stimulating factorRecombinant human GM-CSFGrade feverTransfusion requirementsIntravenous infusionMyelodysplastic syndromePlatelet countAplastic anemiaGranulocyte countMonocyte count